Glycoprotein therapeutic - Boston Therapeutics

Drug Profile

Glycoprotein therapeutic - Boston Therapeutics

Alternative Names: Ipoxyn

Latest Information Update: 07 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boston Therapeutics
  • Class Glycoproteins
  • Mechanism of Action Oxygen carriers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Anaemia; Cardiovascular disorders; Peripheral ischaemia

Most Recent Events

  • 07 Jun 2017 Boston Therapeutics is seeking partners for funding the development of glycoprotein therapeutic as of 28 Mar 2017 .
  • 28 Mar 2017 Suspended - Preclinical for Peripheral ischaemia, Cardiovascular disorders and Anaemia in USA until Boston Therapeutics can secure funds for the compound (IV)
  • 30 May 2014 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top